丹参川芎嗪治疗慢性肺源性心脏病急性发作的疗效

目的：观察丹参川芎嗪注射液对慢性肺源性心脏病急性发作患者肺动脉压（PAP）、动脉氧分压（PaO。）、C反应蛋白（CRP）和内皮素-1（ET-1）的影响。方法：40例慢性肺源性心脏病肺动脉高压患者被随机分为两组，常规治疗组：20例，接受常规治疗；观察组：20例，在常规治疗基础上加用丹参川芎嗪。另选20例健康查体者作为健康对照组。观察治疗后各组PAP、PaO：、CRP、ET-1水平和左室射血分数（LVEF）变化，并进行分析。结果：治疗后与常规治疗组比较，观察组总有效率明显提高（75％比90％），PaOz[（83．87±14．53）mmHg比（92．95±13．54）mmHg]显著升高，平均肺动脉压（mPAP）[（55．43±9．65）mmHg比（45．52±8．89）mm-Hg]显著下降，CRP[（6．37±2．12）mg／L比（3．29±0．84）mg／L]和ET-1[（52．37±20．79）ng／L比（40．29±16．04）ng／L]水平明显下降（P〈0．05～〈0．01）。两组治疗后LVEF升高幅度无显著差异（P〉0．05）。结论：对于慢性肺心病急性发作患者丹参JIJ芎嗪注射液能显著提高临床疗效，改善右心功能，降低平均肺动脉压，改善内皮功能，抑制炎症反应。

Effect of salvia miltiorrhiza and ligustrazine on acute episode of chronic pulmonary heart disease

Objective： To observe effect of salvia miltiorrhiza and ligustrazine injection on patients with acute episode of chronic pulmonary heart disease （CPHD） complicated pulmonary artery hypertension. Methods： A total of 40 CPHD patients with pulmonary artery hypertension were randomly divided into routine treatment group （n= 20, received routine treatment） and observation group （n= 20, received salvia miltiorrhiza and ligustrazine based on routine treatment）. Another 20 healthy subjects were regard as healthy control group. The pulmonary artery pressure （PAP）, partial pressure of oxygen in artery （PaO2） , left ventricular ejection fraction （LVEF） and levels of C--reactive protein （CRP） and endothelin-1 （ET-1） were examined and analyzed in all groups before and after treatment. Results= Af- ter treatment, compared with routine treatment group, there were significant increase in total effective rate （75% vs. 90%） and PaO2（83.87± 14.53） mmHg vs. （92.95 ±13.54） mmHg], and significant decrease in mean PAP [mPAP, （55.43±9.65） mmHgvs. （45.52±8.89） mmHg], CRP[（6.37±2.12） mg/Lvs. （3.29±0.84） mg/L] and ET--1 [ （52.37±20.79） ng/L vs. （40.29±16.04） ng/L] in observation group （P〈0.05-〈0.01）. There was no significant difference in LVEF between the two groups after treatment （P〉0.05）. Conclusion： For patients with acute episode of chronic pulmonary heart disease complicated pulmonary artery hypertension, salvia miltiorrhiza and ligustrazine injection can significantly improve clinical effects, right heart function, decrease mean pulmonary artery pressure, improve endothelial function and inhibit inflammatory reactions.